338 related articles for article (PubMed ID: 26772631)
1. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
[TBL] [Abstract][Full Text] [Related]
2. HPV single-dose vaccination: Impact potential, evidence base and further evaluation.
Stanley M; Dull P
Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
4. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
9. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule.
Brotherton JM
Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867
[TBL] [Abstract][Full Text] [Related]
11. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions.
Dehlendorff C; Sparén P; Baldur-Felskov B; Herweijer E; Arnheim-Dahlström L; Ploner A; Uhnoo I; Kjaer SK
Vaccine; 2018 Oct; 36(43):6373-6378. PubMed ID: 30249423
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily.
Capra G; Giovannelli L; Matranga D; Bellavia C; Guarneri MF; Fasciana T; Scaduto G; Firenze A; Vassiliadis A; Perino A
Hum Vaccin Immunother; 2017 Aug; 13(8):1839-1843. PubMed ID: 28594305
[TBL] [Abstract][Full Text] [Related]
15. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
17. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
[TBL] [Abstract][Full Text] [Related]
19. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.
Min KJ; Kwon SH; Kim S; Kim HJ; Seong SJ; Song YJ; Shin JW; Lee KH; Lim MC; Chung HH; Ju W; Hong JH; Lee JW; Kim JW; Bae DS; Lee JK
J Gynecol Oncol; 2016 May; 27(3):e30. PubMed ID: 27029751
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]